DOCSLIB.ORG

DHEA Inhibits Leukocyte Recruitment Through Regulation of the Integrin Antagonist DEL-1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
DHEA Inhibits Leukocyte Recruitment Through Regulation of the Integrin Antagonist DEL-1 DHEA Inhibits Leukocyte Recruitment through Regulation of the Integrin Antagonist DEL-1 This information is current as Athanasios Ziogas, Tomoki Maekawa, Johannes R. of September 27, 2021. Wiessner, Thi Trang Le, David Sprott, Maria Troullinaki, Ales Neuwirth, Vasiliki Anastasopoulou, Sylvia Grossklaus, Kyoung-Jin Chung, Markus Sperandio, Triantafyllos Chavakis, George Hajishengallis and Vasileia Ismini Alexaki Downloaded from J Immunol published online 24 January 2020 http://www.jimmunol.org/content/early/2020/01/24/jimmun ol.1900746 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Author Choice Freely available online through The Journal of Immunology Author Choice option Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2020 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Published January 24, 2020, doi:10.4049/jimmunol.1900746 The Journal of Immunology DHEA Inhibits Leukocyte Recruitment through Regulation of the Integrin Antagonist DEL-1 Athanasios Ziogas,*,1 Tomoki Maekawa,†,‡,1 Johannes R. Wiessner,x Thi Trang Le,* David Sprott,* Maria Troullinaki,* Ales Neuwirth,* Vasiliki Anastasopoulou,* Sylvia Grossklaus,* Kyoung-Jin Chung,* Markus Sperandio,x Triantafyllos Chavakis,*,{,2 George Hajishengallis,†,2 and Vasileia Ismini Alexaki*,2 Leukocytes are rapidly recruited to sites of inflammation via interactions with the vascular endothelium. The steroid hormone dehydroepiandrosterone (DHEA) exerts anti-inflammatory properties; however, the underlying mechanisms are poorly understood. In this study, we show that an anti-inflammatory mechanism of DHEA involves the regulation of developmental endothelial locus 1 b (DEL-1) expression. DEL-1 is a secreted homeostatic factor that inhibits 2-integrin–dependent leukocyte adhesion, and the subse- Downloaded from quent leukocyte recruitment and its expression is downregulated upon inflammation. Similarly, DHEA inhibited leukocyte adhesion to the endothelium in venules of the inflamed mouse cremaster muscle. Importantly, in a model of lung inflammation, DHEA limited neutrophil recruitment in a DEL-1–dependent manner. Mechanistically, DHEA counteracted the inhibitory effect of inflammation on DEL-1 expression. Indeed, whereas TNF reduced DEL-1 expression and secretion in endothelial cells by diminishing C/EBPb binding to the DEL-1 gene promoter, DHEA counteracted the inhibitory effect of TNF via activation of tropomyosin receptor kinase A (TRKA) b and downstream PI3K/AKT signaling that restored C/EBP binding to the DEL-1 promoter. In conclusion, DHEA restrains neutrophil http://www.jimmunol.org/ recruitment by reversing inflammation-induced downregulation of DEL-1 expression. Therefore, the anti-inflammatory DHEA/DEL-1 axis could be harnessed therapeutically in the context of inflammatory diseases. The Journal of Immunology, 2020, 204: 000–000. ctivation of the endothelium is integral to leukocyte DEL-1 causes elevated leukocyte infiltration under different in- recruitment into inflamed tissues (1, 2). Upon activation flammatory conditions in mice (8, 9, 12, 15, 17–20). Inflammatory A by proinflammatory cytokines, such as TNF, endothelial cytokines, such as IL-17 and TNF, inhibit endothelial DEL-1 ex- cells orchestrate inflammation and leukocyte recruitment, which pression, thereby facilitating leukocyte recruitment and inflamma- is mediated by a cascade of leukocyte–endothelial adhesive in- tion (9, 17, 21). The IL-17–dependent downregulation of DEL-1 teractions (2–4). This cascade is initiated by selectin-mediated expression is reversed by D-series resolvins (RvDs) (21). However, by guest on September 27, 2021 rolling and deceleration of leukocytes on the endothelial surface. little is known about other factors regulating DEL-1 expression. Rolling triggers integrin activation, and activated integrins Dehydroepiandrosterone (DHEA; 5-androsten-3b-hydroxy-17- (primarily of the b2 family) promote firm adhesion of leukocytes one) and its sulfate ester are abundant circulating steroid hor- to the activated endothelium, a prerequisite step for the subse- mones in human adults, whereas their concentration declines with quent leukocyte extravasation (5, 6). age and in inflammatory diseases, such as arthritis and systemic Developmental endothelial locus 1 (DEL-1; also designated lupus erythematosus (22–26). In humans, DHEA is produced in EGF-like repeats and discoidin domains 3 [EDIL3]) is a glycoprotein the adrenal cortex, the gonads, and the CNS (27–30). In tissues, secreted by endothelial and other cells and has anti-inflammatory DHEA displays anti-inflammatory properties, including inhibition properties (7–16). DEL-1 interferes with b2-integrin–dependent of leukocyte recruitment (31, 32). DHEA can bind to nuclear re- adhesion of leukocytes to endothelial ICAM-1, thereby restraining ceptors, such as estrogen receptor a and b (33, 34). Moreover, it leukocyte recruitment (8, 9). Consistently, genetic deletion of was shown to bind to G protein–coupled receptors in endothelial *Institute of Clinical Chemistry and Laboratory Medicine, University Clinic Grant Agreement (765704 to V.I.A.), the European Research Council (DEMETINL Carl Gustav Carus, Technische Universita¨t Dresden, 01307 Dresden, Germany; to T.C.), and by National Institutes of Health grants (DE015254, DE024153, and †Department of Microbiology, Penn Dental Medicine, University of Pennsylvania, DE024716 to G.H. and DE026152 to G.H. and T.C.). Philadelphia, PA 19104; ‡Research Center for Advanced Oral Science, Graduate Address correspondence and reprint requests to Dr. Athanasios Ziogas and School of Medical and Dental Sciences, Niigata University, 951-8514 Niigata, Japan; x Dr. Vasileia Ismini Alexaki, Institute for Clinical Chemistry and Laboratory Walter Brendel Centre of Experimental Medicine and Institute of Cardiovascular Medicine, Technische Universita¨t Dresden, Fetscherstrasse 74, 01307 Dresden, Physiology and Pathophysiology, BioMedical Centre, Ludwig Maximilians Univer- { Germany. E-mail addresses: [email protected] (A.Z.) sity of Munich, 81377 Planegg-Martinsried, Germany; and Centre for Cardiovascu- and [email protected] (V.I.A.) lar Science, Queen’s Medical Research Institute, University of Edinburgh, EH16 4TJ Edinburgh, United Kingdom Abbreviations used in this article: BAL, bronchoalveolar lavage; ChIP, chroma- tin immunoprecipitation; DEL-1, developmental endothelial locus 1; DHEA, 1Equally contributing first authors. dehydroepiandrosterone; EAE, experimental autoimmune encephalomyelitis; 2Equally contributing senior authors. hDEL-1-promoter-Luc, human DEL-1 promoter/luciferase reporter plasmid; NGF, nerve growth factor; qPCR, quantitative real-time PCR; siRNA, small interfering ORCIDs: 0000-0002-4597-1316 (T.M.); 0000-0002-0471-1462 (J.R.W.); 0000-0002- RNA; TRKA, tropomyosin-related kinase A; WT, wild-type. 4060-1797 (T.T.L.); 0000-0003-4668-4316 (A.N.); 0000-0002-7689-3613 (M.S.). This article is distributed under The American Association of Immunologists, Inc., Received for publication July 2, 2019. Accepted for publication December 27, 2019. Reuse Terms and Conditions for Author Choice articles. This work was supported by grants from the Deutsche Forschungsgemeinschaft (AL1686/2-2 and AL1686/3-1 to V.I.A., CH279/6-2 to T.C., SFB/TRR 205 to V.I. Copyright Ó 2020 by The American Association of Immunologists, Inc. 0022-1767/20/$37.50 A. and T.C., and SP621/5-1 and SFB914 TP B01 to M.S.), the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie www.jimmunol.org/cgi/doi/10.4049/jimmunol.1900746 2 THE DHEA/DEL-1 ANTI-INFLAMMATORY AXIS and neuronal cells (35, 36). Additionally, it binds and activates the analysis using Ly-6G– allophycocyanin (1A8; BD Pharmingen, Heidel- nerve growth factor (NGF) receptor, tropomyosin-related kinase A berg, Germany) and CD11b–Alexa Fluor 488 (M1/7; BD Pharmingen) (TRKA), in neuronal and microglial cells, thereby triggering Abs. Experiments were approved by the Landesdirektion Sachsen, Dresden, Germany. downstream AKT signaling (30, 37, 38). However, its exact mech- anisms of action, especially in the context of recruitment regulation, Cell lines, primary cells, and cell treatments remain largely unknown (39, 40). HEK-293T cells (American Type Culture Collection, Manassas, VA) were In the current study, we demonstrate that DHEA mitigates cultured in DMEM (Life Technologies) supplemented with 10% FBS, 100 U/ml leukocyte adhesion efficiency in the LPS-induced cremaster muscle penicillin, and 100 mg/ml streptomycin at 37˚C and 5% CO2.HUVECs inflammation model and reduces neutrophil recruitment in the LPS- (Lonza, Basel, Switzerland) were cultured on 0.2% gelatin-coated plates in induced lung inflammation model. Mechanistic studies revealed Endothelial Cell Growth Medium-2
Load more

Recommended publications
  • Insulin and Insulin-Like Growth Factor II Permit Nerve Growth Factor Binding
    Proc. Natl. Acad. Sci. USA Vol. 81, pp. 2562-2566, April 1984 Neurobiology Insulin and insulin-like growth factor II permit nerve growth factor binding and the neurite formation response in cultured human neuroblastoma cells (axons/differentiation/nerve growth factor receptor/pheochromocytoma PC12) ESPERANZA RECIO-PINTO, FREDERICK F. LANG, AND DOUGLAS N. ISHII* Department of Pharmacology and Cancer Research Center, College of Physicians and Surgeons of Columbia University, New York, NY 10032 Communicated by I. S. Edelman, January 3, 1984 ABSTRACT In serum-free medium, SH-SY5Y human mouse saliva (16); purity was confirmed by the single band in neuroblastoma cells specifically and reversibly lost the capaci- polyacrylamide gels subjected to isoelectric focusing (pH ty to bind 1251-labeled nerve growth factor (NGF) to the high- 3.5-10), or NaDodSO4 gel electrophoresis and by bioassay affinity sites (slow sites) and to respond by neurite outgrowth, (17). Anti-insulin antiserum was from Cappel Laboratories unless physiological concentrations of insulin or insulin-like (Cochranville, PA). The cloned cell line SH-SY5Y (7) was a growth factor II were present. In serum-containing medium, kind gift from June L. Biedler and Barbara A. Spengler. anti-insulin antiserum decreased the neurite formation re- Cells between passage numbers 9 and 29 were studied. The sponse to NGF, and insulin supplementation increased the cloned PC12 cell line (18) was the kind gift of Lloyd A. number of available NGF slow sites. The low-affinity NGF fast Greene and was subcloned prior to use. sites are absent from SH-SY5Y cells and did not emerge on Cell Culture.
    [Show full text]
  • Nerve Growth Factor- and Neurotrophin-3-Induced Changes in Nociceptive Threshold and the Release of Substance P from the Rat Isolated Spinal Cord
    The Journal of Neuroscience, November 1, 1997, 17(21):8459–8467 Nerve Growth Factor- and Neurotrophin-3-Induced Changes in Nociceptive Threshold and the Release of Substance P from the Rat Isolated Spinal Cord Marzia Malcangio, Neil E. Garrett, Simon Cruwys, and David R. Tomlinson Department of Pharmacology, St. Bartholomew’s and the Royal London School of Medicine and Dentistry, Queen Mary and Westfield College, London E1 4NS, United Kingdom Acute superfusion of nerve growth factor (NGF; 1–100 ng/ml) istration, NGF had induced thermal and mechanical hyperalge- through a naive rat spinal cord preparation did not alter basal or sia in the rat hindpaw, and NT-3 had induced mechanical, but electrically evoked release of substance P-like immunoreactiv- not thermal, hypoalgesia. NT-3 administered six times over a 2 ity (SP-LI). In contrast, neurotrophin-3 (NT-3; 1–100 ng/ml), week period (at 1 mg/kg) did not alter thermal threshold but although not modifying SP-LI basal outflow, dose-dependently significantly reduced electrically evoked release of SP-LI from inhibited the electrically evoked, but not capsaicin (10 nM)- the spinal cord. An identical treatment regimen with 1 mg/kg induced, release of the peptide. This NT-3 (10 ng/ml)-induced NGF induced a significant increase in evoked release of SP-LI. inhibition persisted even in the presence of 100 ng/ml NGF in However, this was not associated with a significant hyperalge- the perfusion fluid and was still significant when the evoked sia. Although finding that NGF-induced hyperalgesia does not release of SP-LI was enhanced by a prolonged in vivo treatment clearly correlate with changes in the release of SP-LI in the with NGF.
    [Show full text]
  • Differential Effects of Dehydroepiandrosterone and Testosterone in Prostate and Colon Cancer Cell Apoptosis: the Role of Nerve Growth Factor (NGF) Receptors
    DHEA e testosterona e apoptose no câncer de próstata e de colon, papel do NGF – fator de crescimento neural. Differential effects of dehydroepiandrosterone and testosterone in prostate and colon cancer cell apoptosis: the role of nerve growth factor (NGF) receptors. Anagnostopoulou V1, Pediaditakis I, Alkahtani S, Alarifi SA, Schmidt EM, Lang F, Gravanis A, Charalampopoulos I, Stournaras C. Endocrinology. 2013 Jul;154(7):2446-56. Author information 1 Department of Biochemistry, University of Crete Medical School, GR-71003 Heraklion, Greece. Abstract Tumor growth is fostered by inhibition of cell death, which involves the receptiveness of tumor to growth factors and hormones. We have recently shown that testosterone exerts proapoptotic effects in prostate and colon cancer cells through a membrane-initiated mechanism. In addition, we have recently reported that dehydroepiandrosterone (DHEA) can control cell fate, activating nerve growth factor (NGF) receptors, namely tropomyosin-related kinase (Trk)A and p75 neurotrophin receptor, in primary neurons and in PC12 tumoral cells. NGF was recently involved in cancer cell proliferation and apoptosis. In the present study, we explored the cross talk between androgens (testosterone and DHEA) and NGF in regulating apoptosis of prostate and colon cancer cells. DHEA and NGF strongly blunted serum deprivation-induced apoptosis, whereas testosterone induced apoptosis of both cancer cell lines. The antiapoptotic effect of both DHEA and NGF was completely reversed by testosterone. In line with this, DHEA or NGF up-regulated, whereas testosterone down- regulated, the expression of TrkA receptor. The effects of androgens were abolished in both cell lines in the presence of TrkA inhibitor. DHEA induced the phosphorylation of TrkA and the interaction of p75 neurotrophin receptor with its effectors, Rho protein GDP dissociation inhibitor and receptor interacting serine/threonine-protein kinase 2.
    [Show full text]
  • Effects of BNN27, a Novel C17-Spiroepoxy Steroid Derivative
    www.nature.com/scientificreports OPEN Efects of BNN27, a novel C17- spiroepoxy steroid derivative, on experimental retinal detachment- Received: 18 July 2017 Accepted: 26 June 2018 induced photoreceptor cell death Published: xx xx xxxx Pavlina Tsoka 1,4, Hidetaka Matsumoto4, Daniel E. Maidana 4, Keiko Kataoka4, Irene Naoumidi1, Achille Gravanis2,3, Demetrios G. Vavvas4 & Miltiadis K. Tsilimbaris1 Retinal detachment (RD) leads to photoreceptor cell death secondary to the physical separation of the retina from the underlying retinal pigment epithelium. Intensifying photoreceptor survival in the detached retina could be remarkably favorable for many retinopathies in which RD can be seen. BNN27, a blood-brain barrier (BBB)-permeable, C17-spiroepoxy derivative of dehydroepiandrosterone (DHEA) has shown promising neuroprotective activity through interaction with nerve growth factor receptors, TrkA and p75NTR. Here, we administered BNN27 systemically in a murine model of RD. TUNEL+ photoreceptors were signifcantly decreased 24 hours post injury after a single administration of 200 mg/kg BNN27. Furthermore, BNN27 increased infammatory cell infltration, as well as, two markers of gliosis 24 hours post RD. However, single or multiple doses of BNN27 were not able to protect the overall survival of photoreceptors 7 days post injury. Additionally, BNN27 did not induce the activation/phosphorylation of TrkAY490 in the detached retina although the mRNA levels of the receptor were increased in the photoreceptors post injury. Together, these fndings, do not demonstrate neuroprotective activity of BNN27 in experimentally-induced RD. Further studies are needed in order to elucidate the paradox/contradiction of these results and the mechanism of action of BNN27 in this model of photoreceptor cell damage.
    [Show full text]
  • Brain-Derived Neurotrophic Factor, and Neurotrophin 3 in the Rat
    Proc. Nati. Acad. Sci. USA Vol. 88, pp. 10352-10356, November 1991 Neurobiology Expanded distribution of mRNA for nerve growth factor, brain-derived neurotrophic factor, and neurotrophin 3 in the rat brain after colchicine treatment (neurotrophic factor/regulation/localization/in situ hybridization) S. CECCATELLI*t, P. ERNFORSt, M. J. VILLAR*§, H. PERSSONt, AND T. HOKFELT* Departments of *Histology and Neurobiology and of tMedical Chemistry, Laboratory of Molecular Neurobiology, Karolinska Institute, Stockholm, Sweden; and lnstituto de Neurobiologfa, Buenos Aires, Argentina Contributed by T. Hokfelt, August 16, 1991 ABSTRACT The effect of intracerebroventricular iqjec- motoneurons after axotomy (11) and after intracerebroven- tion of the mitosis inhibitor colchicine on expression of mRNA tricular injection of colchicine (12). for nerve growth factor (NGF), brain-derived neurotrophic During the last years much interest has been focused on factor (BDNF), and neurotrophin 3 was studied in the rat brain NGF (13), the first member of a family of structurally related with in situ hybridization. Colchicine up-regulates mRNA for neurotrophic factors including brain-derived neurotrophic NGF and BDNF in many of the neuronal systems normally factor (BDNF) (14, 15), neurotrophin 3 (NT3; also called expressing these factors. In addition, after colchicine treatment hippocampus-derived neurotrophic factor) (16-20), and neu- NGF and BDNF mRNAs were localized in several brain areas rotrophin 4 (21). NGF, BDNF, and NT3 are all expressed in where they normally
    [Show full text]
  • Supplementary Table 2
    Supplementary Table 2. Differentially Expressed Genes following Sham treatment relative to Untreated Controls Fold Change Accession Name Symbol 3 h 12 h NM_013121 CD28 antigen Cd28 12.82 BG665360 FMS-like tyrosine kinase 1 Flt1 9.63 NM_012701 Adrenergic receptor, beta 1 Adrb1 8.24 0.46 U20796 Nuclear receptor subfamily 1, group D, member 2 Nr1d2 7.22 NM_017116 Calpain 2 Capn2 6.41 BE097282 Guanine nucleotide binding protein, alpha 12 Gna12 6.21 NM_053328 Basic helix-loop-helix domain containing, class B2 Bhlhb2 5.79 NM_053831 Guanylate cyclase 2f Gucy2f 5.71 AW251703 Tumor necrosis factor receptor superfamily, member 12a Tnfrsf12a 5.57 NM_021691 Twist homolog 2 (Drosophila) Twist2 5.42 NM_133550 Fc receptor, IgE, low affinity II, alpha polypeptide Fcer2a 4.93 NM_031120 Signal sequence receptor, gamma Ssr3 4.84 NM_053544 Secreted frizzled-related protein 4 Sfrp4 4.73 NM_053910 Pleckstrin homology, Sec7 and coiled/coil domains 1 Pscd1 4.69 BE113233 Suppressor of cytokine signaling 2 Socs2 4.68 NM_053949 Potassium voltage-gated channel, subfamily H (eag- Kcnh2 4.60 related), member 2 NM_017305 Glutamate cysteine ligase, modifier subunit Gclm 4.59 NM_017309 Protein phospatase 3, regulatory subunit B, alpha Ppp3r1 4.54 isoform,type 1 NM_012765 5-hydroxytryptamine (serotonin) receptor 2C Htr2c 4.46 NM_017218 V-erb-b2 erythroblastic leukemia viral oncogene homolog Erbb3 4.42 3 (avian) AW918369 Zinc finger protein 191 Zfp191 4.38 NM_031034 Guanine nucleotide binding protein, alpha 12 Gna12 4.38 NM_017020 Interleukin 6 receptor Il6r 4.37 AJ002942
    [Show full text]
  • Review Multifunctional Roles of Growth Factors Or Biologically Active Peptides in Salivary Glands and Saliva
    Oral Med Pathol 12 (2008) 115 Review Multifunctional roles of growth factors or biologically active peptides in salivary glands and saliva Masahiko Mori1, Shinichiro Sumitomo1, Prashanta Shrestha2, Shiro Tanaka1, Yoshiaki Takai1, Michio Shikimori1 1Department of Oral-Maxillofacial Surgery, Division of Oral Pathogenesis and Disease Control, Asahi University School of Dentistry, Gifu, Japan 2Division of Oral-Maxillofacial Surgery, Katmandu University Medical School, Katmandu, Nepal Abstract: Salivary glands secrete saliva which contains mucins, antimicrobial substances and growth factors. Since epidermal growth factor (EGF) and nerve growth factor (NGF) were demonstrated in murine submandibular glands (SMGs), several growth factors and biologically-active peptides have been studied in the human or other mammalian salivary glands and saliva. These growth factors may have a functional role in cell migration, proliferation and maturation within not only salivary glands but also other organs. In the SMGs of mice and rats, EGF, NGF and other known growth factors are usually synthesized in granular convoluted tubule cells (GCT). However, human SMGs are devoid of GCT cells, and growth factors in human salivary glands are usually produced in striated ducts. These findings suggest an evolutionary trace of ductal cells in mammals. The present review describes expression patterns of the following salivary gland growth factors: nerve growth factor (NGF); transforming growth factor α and β (TGF-α/β) bone morphogenetic protein (BMP); insulin-like growth
    [Show full text]
  • Nerve Growth Factor Promotes Expression of Novel Genes in Intervertebral Disc Cells That Regulate Tissue Degradation
    J Neurosurg Spine 21:653–661, 2014 ©AANS, 2014 Nerve growth factor promotes expression of novel genes in intervertebral disc cells that regulate tissue degradation Laboratory investigation TING-HSIEN KAO, M.D.,1,3,4 YI-JEN PENG, M.D., PH.D.,2 HSI-KAI TSOU, M.D., PH.D.,3,5 DONALD M. SALTER, M.D.,6 AND HERNG-SHENG LEE, M.D., PH.D.1,2 1Graduate Institute of Medical Science, National Defense Medical Center, and 2Department of Pathology, Tri-Service General Hospital and National Defense Medical Center, Taipei; 3Department of Neurosurgery, Taichung Veterans General Hospital, Taichung; Departments of 4Acupressure Technology and 5Early Childhood Care and Education, Jen-Teh Junior College of Medicine, Nursing and Management, Miaoli County, Taiwan, Republic of China; and 6Osteoarticular Research Group, Molecular Medicine Center, Institute of Genetics and Molecular Medicine, University of Edinburgh, United Kingdom Object. Increased neurotrophin activity in degenerative intervertebral discs (IVDs) is one potential cause of chronic low-back pain (LBP). The aim of the study was to assess if nerve growth factor (NGF) might alter gene expression of IVD cells and contribute to disc degeneration by enhancing expression or activity of factors that cause breakdown of IVD matrix. Methods. Rat-tail IVD cells were stimulated by NGF and subjected to microarray analysis. Real-time poly- merase chain reaction, Western blotting, and immunocytochemistry of rat and human IVD cells and tissues treated with NGF in vitro in the absence or presence of the NGF inhibitor Ro 08-2750 were used to confirm findings of the microarray studies. Phosphorylation of mitogen-activated protein kinase (MAPK) was used to identify cell signaling pathways involved in NGF stimulation in the absence or presence of Ro 08-2750.
    [Show full text]
  • Increased Encapsulated Cell Biodelivery of Nerve Growth Factor in the Brain by Transposon-Mediated Gene Transfer
    Gene Therapy (2012) 19, 1010 --1017 & 2012 Macmillan Publishers Limited All rights reserved 0969-7128/12 www.nature.com/gt ORIGINAL ARTICLE Increased encapsulated cell biodelivery of nerve growth factor in the brain by transposon-mediated gene transfer L Fjord-Larsen,1, P Kusk1, DF Emerich2, C Thanos3, M Torp1, B Bintz3, J Tornøe1, AH Johnsen4 and LU Wahlberg2 Nerve growth factor (NGF) is a potential therapeutic agent for Alzheimer’s disease (AD) as it has positive effects on the basal forebrain cholinergic neurons whose degeneration correlates with the cognitive decline in AD. We have previously described an encapsulated cell biodelivery device, NsG0202, capable of local delivery of NGF by a genetically modified human cell line, NGC-0295. The NsG0202 devices have shown promising safety and therapeutic results in a small phase 1b clinical study. However, results also show that the NGF dose could advantageously be increased. We have used the sleeping beauty transposon expression technology to establish a new clinical grade cell line, NGC0211, with at least 10 times higher NGF production than that of NGC-0295. To test whether encapsulation of this cell line provides a relevant dose escalation step in delivering NGF for treatment of the cognitive decline in AD patients, we have validated the bioactivity of devices with NGC0211 and NGC-0295 cells in normal rat striatum as well as in the quinolinic acid striatal lesion model. These preclinical animal studies show that implantation of devices with NGC0211 cells lead to significantly higher NGF output, which in both cases correlate with highly improved potency. Gene Therapy (2012) 19, 1010--1017; doi:10.1038/gt.2011.178; published online 24 November 2011 Keywords: encapsulated cell biodelivery; sleeping beauty transposon; NGF; preclinical validation; cholinergic neurons; rat QA model INTRODUCTION zoonosis and xenogenic reactions from the secretome, a human Alzheimer’s disease (AD) is a progressive, fatal neurodegenerative cell line is preferred for clinical applications.
    [Show full text]
  • Nerve Growth Factor Regulates Tyrosine Hydroxylase Gene Transcription Through a Nucleoprotein Complex That Contains C-Fos
    Downloaded from genesdev.cshlp.org on September 30, 2021 - Published by Cold Spring Harbor Laboratory Press Nerve growth factor regulates tyrosine hydroxylase gene transcription through a nucleoprotein complex that contains c-Fos Elena Gizang-Ginsberg and Edward B. Ziff 1 Department of Biochemistry and Kaplan Cancer Center, New York University Medical Center, New York, New York 10016 USA We have studied nerve growth factor (NGF) regulation of the expression of the tyrosine hydroxylase (TH) gene in PC12 cells. The TH gene encodes the initial and rate-limiting enzyme of the catecholamine biosynthetic pathway. We show that the TH gene is transiently transcriptionally induced by a mechanism reliant on new protein synthesis during 1-2 hr of NGF stimulation, a time following the induction of the c-los gene at 15 min post-NGF treatment. A potential regulatory sequence located within the TH gene promoter, the TH-FSE, shares homology to a known regulatory element, the fat-specific element (FSE), which is found upstream from genes activated during adipocyte differentiation and binds the Fos-Jun transcription factor complex. We show that the TH-FSE DNA sequence elevates the basal level of transcription from the rat TH promoter and is required for NGF inducibility. This DNA element binds authentic Fos-Jun products produced by in vitro translation. We demonstrate further that the TH-FSE can bind proteins present in PC12 nuclear extracts in a sequence-specific manner. The DNA/nucleoprotein complex that forms increases in abundance during NGF stimulation and reaches a maximum level at 4 hr of treatment. Antibody inhibition studies utilizing an anti-Fos antibody indicate that Fos and/or Fos-related antigen(s) associate with the TH-FSE and suggest that the Fos protein family contributes to the regulation of TH in vivo.
    [Show full text]
  • Ontogenesis of Nerve Growth Factor
    Pediatr. Res. 16: 520-524 (1982) Ontogenesis of Nerve Growth Factor and Epidermal Growth Factor in Submaxillary Glands and Nerve Growth Factor in Brains of Immature Male Mice: Correlation with Ontogenesis of Serum Levels of Thyroid Hormones P. WALKER, M. E. WEICHSEL, JR.,'42' D. EVELETH, AND D. A. FISHER Department of Pediatrics, Harbor-UCLA Medical Center, 1000 West Carson Street, Torrance, California, USA Summary between 11 and 32 days of age. The known increase in mouse serum testosterone to adult male levels between 4-12 wk of age Using specific and sensitive radioimmunoassa~sfor may be a factor in the late increase in NGF and EGF elevations growth factor (NGF) and epidermal growth factor (EGF), we after 32 days of age. studied the developmental profde of NGF and EGF concentrations in male mouse submaxillary gland (SMG) from 2-60 days of age. We measured NGF concentrations in mouse cerebellum, cerebral Nerve growth factor (NGF) and epidermal growth factor (EGF) cortex, and brain stem from ages 2-32 days. In addition, we are found in highest concentrations in the submaxillary gland assessed mouse serum thyroxine (T4) and triiodothyronine (T3) (SMG) of the adult male mouse (13,22). Both proteins are found levels in SePerate groups of animals ranging from 5-50 days of in peritubular cells (32, 35) and are released concomitantly into age. Mean SMG EGF content and concentration exceeded that saliva (16,27). ~0thhave C-terminus arginine residues (2, 13) and of NGF between 2 and 18 days of age. At all subsequent ages, exist in SMG as high molecular weight complexes with specific however, mean NGF and EGF content and concentration were arginine esteropeptidase subunits (34).
    [Show full text]
  • Nerve Growth Factor and Neurotrophin-3 Mediate Survival of Pulmonary Plasma Cells During the Allergic Airway Inflammation1
    The Journal of Immunology Nerve Growth Factor and Neurotrophin-3 Mediate Survival of Pulmonary Plasma Cells during the Allergic Airway Inflammation1 Melanie Abram,* Michael Wegmann,*† Verena Fokuhl,‡ Sanchaita Sonar,* Elke Olga Luger,‡¶ Sebastian Kerzel,§ Andreas Radbruch,‡ Harald Renz,2* and Michael Zemlin2,3§ Allergen-specific Abs play a pivotal role in the induction and maintenance of allergic airway inflammation. During secondary immune responses, plasma cell survival and Ab production is mediated by extrinsic factors provided by the local environment (survival niches). It is unknown whether neurotrophins, a characteristic marker of allergic airway inflammation, influence plasma cell survival in the lung. Using a mouse model of allergic asthma, we found that plasma cells from the lung and spleen are distinct subpopulations exhibiting differential expression patterns of neurotrophins and their receptors (Trks). In vitro, the nerve growth factor (NGF) and neurotrophin-3 (NT3) led to a dose-dependent increase in viability of isolated pulmonary plasma cells due to up-regulation of the antiapoptotic Bcl2 pathway. In parallel, the expression of transcription factors that stimulate the production of immunoglobulins (X-box binding protein 1 and NF-␬B subunit RelA) was enhanced in plasma cells treated with NGF and NT3. These findings were supported in vivo. When the NGF pathway was blocked by intranasal application of a selective TrkA inhibitor, sensitized mice showed reduced numbers of pul- monary plasma cells and developed lower levels of allergen-specific and total serum IgE in response to OVA inhalation. This suggests that in the allergic airway inflammation, NGF/TrkA-mediated pulmonary IgE production contributes significantly to serum-IgE levels.
    [Show full text]